ADAR1 Capital Management LLC Sells 22,741 Shares of Context Therapeutics Inc. (NASDAQ:CNTX)

ADAR1 Capital Management LLC cut its holdings in Context Therapeutics Inc. (NASDAQ:CNTX) by 6.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 351,094 shares of the company’s stock after selling 22,741 shares during the period. ADAR1 Capital Management LLC owned approximately 0.47% of Context Therapeutics worth $369,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Landscape Capital Management L.L.C. acquired a new position in Context Therapeutics during the fourth quarter worth about $94,000. Geode Capital Management LLC increased its stake in shares of Context Therapeutics by 9.2% in the fourth quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock valued at $661,000 after buying an additional 52,830 shares during the period. Franklin Resources Inc. boosted its position in Context Therapeutics by 115.9% during the 4th quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company’s stock worth $4,204,000 after buying an additional 2,149,392 shares during the period. Clear Harbor Asset Management LLC grew its holdings in Context Therapeutics by 60.6% during the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after acquiring an additional 21,804 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Context Therapeutics during the third quarter valued at $89,000. Institutional investors own 14.03% of the company’s stock.

Analyst Ratings Changes

CNTX has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Context Therapeutics in a research note on Friday, March 21st. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research note on Friday, March 21st. Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th. Finally, JMP Securities began coverage on shares of Context Therapeutics in a report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Context Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $6.17.

Context Therapeutics Price Performance

NASDAQ:CNTX opened at $0.60 on Monday. The company has a market cap of $53.74 million, a P/E ratio of -0.66 and a beta of 2.18. Context Therapeutics Inc. has a 1 year low of $0.55 and a 1 year high of $2.75. The stock’s fifty day moving average price is $0.80 and its two-hundred day moving average price is $1.33.

Context Therapeutics (NASDAQ:CNTX) last posted its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. On average, analysts expect that Context Therapeutics Inc. will post -0.51 earnings per share for the current fiscal year.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.